Holen Sie sich die Stockscreener-App
11.13
0.23%
0.025
Handel nachbörslich:
11.30
0.17
+1.53%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$11.11
Offen:
$11.15
24-Stunden-Volumen:
2.97M
Relative Volume:
1.60
Marktkapitalisierung:
$752.05M
Einnahmen:
$796.00M
Nettoeinkommen (Verlust:
$-136.49M
KGV:
-5.3254
EPS:
-2.09
Netto-Cashflow:
$-64.24M
1W Leistung:
-22.65%
1M Leistung:
-28.61%
6M Leistung:
-65.87%
1J Leistung:
-73.25%
1-Tages-Spanne:
$11.01
$11.82
1-Wochen-Bereich:
$9.98
$12.47
52-Wochen-Spanne:
$9.98
$47.60
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Vergleichen Sie TNDM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
11.13 | 750.36M | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The Globe and Mail
Software correction coming for faulty insulin pumps - Cleveland.com
Diabetes Warning Issued Over Insulin Pump Error - Newsweek
Tandem Diabetes upgraded at Citi on risk-reward setup - MSN
5 Insightful Analyst Questions From Tandem Diabetes’s Q2 Earnings Call - Yahoo Finance
Published on: 2025-08-13 16:11:40 - 선데이타임즈
Tandem Diabetes Care: Navigating Volatility and Innovation in a Polarized Market - AInvest
Tandem Diabetes' Recent Surge: Is This the Start of a Long-Term Rally or a Short-Lived Rebound? - AInvest
Tandem Diabetes Care Shares Rise After Upgrade From Citigroup - MarketScreener
Tandem Diabetes upgraded to Neutral by Citi, citing shift in risk-reward setup - AInvest
Tandem Diabetes stock upgraded at Citi (TNDM:NASDAQ) - Seeking Alpha
Tandem Diabetes at Canaccord Conference: Strategic Shifts and Market Focus - Investing.com Canada
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know - TradingView
Tandem Diabetes Care Stock (TNDM) Opinions on Q2 2025 Earnings Miss - Quiver Quantitative
Citigroup Upgrades Tandem Diabetes Care to Neutral From Sell, Adjusts Price Target to $10.35 From $10 - MarketScreener
Citi Upgrades Tandem Diabetes Care to Neutral, Raises PT to $10.35 - AInvest
TNDM Q2 Deep Dive: Margin Pressures and Strategic Shifts Offset Sales Growth - Yahoo Finance
Insider Buying: John Sheridan Acquires Shares of Tandem Diabetes Care Inc (TNDM) - GuruFocus
CFRA Maintains Hold Rating on Tandem Diabetes Care with $22 Price Target - AInvest
Tandem Diabetes Downgraded to Hold by Lake Street Amid Valuation Concerns - AInvest
Tandem Diabetes Care's 2025 Q2 Earnings Call: Unpacking Contradictions in CMS Proposals, Pharmacy Strategies, and Renewal Growth - AInvest
CFRA slashes Tandem Diabetes Care stock price target on GLP-1 risks - Investing.com Canada
Tandem Diabetes Care: Pioneering the Future of Diabetes Management and a High-Conviction Growth Play in 2025 - AInvest
Tandem Diabetes Care Inc. Pipeline Analysis Report 2025: A Comprehensive Guide to the Company's Product Pipeline and Developmental Products - AInvest
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Benzinga
TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up - TradingView
Tandem Diabetes Care Inc. Forms Bullish Flag — Upside AheadScalable Portfolio Growth Suggestions Released - metal.it
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say - MSN
Tandem Diabetes projects $1B sales for 2025 as international growth, pharmacy channel, and product innovation drive outlook - MSN
Tandem Diabetes Care: Earnings Miss Confirms Bear CaseDowngrade To Sell (NASDAQ:TNDM) - Seeking Alpha
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
What does recent volatility data suggest for Tandem Diabetes Care Inc.Technical Analysis of Growth Stock Opportunities - Newser
Medtech Executives Monitor CMS Payment Proposal for Diabetes Technology - AInvest
How to build a custom watchlist for Tandem Diabetes Care Inc.Buy Zone Strategy with Pattern Recognition - Newser
Will Tandem Diabetes Care Inc. outperform the marketSmart Trend Analysis With Buy Point Cues - Newser
Chart based exit strategy for Tandem Diabetes Care Inc.Free Trade Ready Stock Watch for Short Term - Newser
How high can Tandem Diabetes Care Inc. stock goReal Time Screener for Growth Trades - Newser
Tandem Diabetes Care Inc. stock retracement – recovery analysisSafe Momentum Strategy With Trend Analysis - Newser
Tandem downgraded to Neutral at Piper Sandler on softer outlook - MSN
Tandem Diabetes Care Inc.’s volatility index tracking explainedWatchlist Summary for Active Day Traders - Newser
Tandem Diabetes Care’s Earnings Call Highlights Growth and Challenges - The Globe and Mail
Tandem Diabetes Care issues voluntary correction for insulin pumps - Medical Buyer
Tandem Diabetes Care shares rise 4.31% intraday after UBS adjusts price target to $17. - AInvest
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - MedTech Dive
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q2 2025 Earnings Call Transcript - Insider Monkey
Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities - TipRanks
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock - AOL.com
Tandem Diabetes Care Gains FDA Clearance for SteadiSet - TipRanks
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Beats Revenue Estimates - MSN
Tandem Diabetes Care (TNDM.O) Sees Sharp Intraday Decline: What’s Behind the Move? - AInvest
Tandem Diabetes Care issues voluntary device correction for certain insulin pumps - Reuters
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):